Pathology and Lab Medicine

1-16 of 27

• 

  RestartResume

  Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs

  RestartResume

  Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs

  CME/CE

  Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs

  Sara A. Hurvitz, MD, FACP; Tiffany Traina, MD

  0.50 credits

  • 

    

    Sara A. Hurvitz, MD, FACP

  • 

    

    Tiffany Traina, MD

  0.50 credits

• 

  RestartResume

  The Power of Timing: Therapies That Change Outcomes

  RestartResume

  The Power of Timing: Therapies That Change Outcomes

  MinuteCE®

  The Power of Timing: Therapies That Change Outcomes

  Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD

  1.00 program credit

  • 

    

    Scott T. Tagawa, MD, MS

  • 

    

    Mary-Ellen Taplin, MD

  1.00 program credit

• 

  RestartResume

  Precision in Practice—Bringing Targeted Therapy to mHSPC

  RestartResume

  Precision in Practice—Bringing Targeted Therapy to mHSPC

  MinuteCE®

  Precision in Practice—Bringing Targeted Therapy to mHSPC

  Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD

  1.00 program credit

  • 

    

    Scott T. Tagawa, MD, MS

  • 

    

    Mary-Ellen Taplin, MD

  1.00 program credit

• 

  RestartResume

  Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients

  RestartResume

  Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients

  MinuteCE®

  Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients

  Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD

  1.00 program credit

  • 

    

    Scott T. Tagawa, MD, MS

  • 

    

    Mary-Ellen Taplin, MD

  1.00 program credit

• 

  RestartResume

  ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act

  RestartResume

  ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act

  MinuteCE®

  ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act

  Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD

  1.00 program credit

  • 

    

    Scott T. Tagawa, MD, MS

  • 

    

    Mary-Ellen Taplin, MD

  1.00 program credit

• 

  RestartResume

  Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer

  RestartResume

  Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer

  CME/CE

  Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer

  Susana Campos, MD, MPH; Robert Coleman, MD, FACOG

  1.00 credit

  • 

    

    Susana Campos, MD, MPH

  • 

    

    Robert Coleman, MD, FACOG

  • 

    

    Debra Richardson, MD

  1.00 credit

• 

  RestartResume

  Targeting PTEN: Why It Matters

  RestartResume

  Targeting PTEN: Why It Matters

  MinuteCE®

  Targeting PTEN: Why It Matters

  Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD

  1.00 program credit

  • 

    

    Scott T. Tagawa, MD, MS

  • 

    

    Mary-Ellen Taplin, MD

  1.00 program credit

• 

  MinuteCE®

  Treatment Intensification in HSPC: From Risk Stratification to Precision Medicine

  Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD

  1.00 credit 10 episodes

  • 

    

    Scott T. Tagawa, MD, MS

  • 

    

    Mary-Ellen Taplin, MD

  1.00 credit 10 episodes

• 

  RestartResume

  De Novo mHSPC: Recognizing the Patients Who Need More

  RestartResume

  De Novo mHSPC: Recognizing the Patients Who Need More

  MinuteCE®

  De Novo mHSPC: Recognizing the Patients Who Need More

  Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD

  1.00 program credit

  • 

    

    Scott T. Tagawa, MD, MS

  • 

    

    Mary-Ellen Taplin, MD

  1.00 program credit

• 

  RestartResume

  Winning the Battle Against Side Effects: Adverse Event Management in HSPC

  RestartResume

  Winning the Battle Against Side Effects: Adverse Event Management in HSPC

  MinuteCE®

  Winning the Battle Against Side Effects: Adverse Event Management in HSPC

  Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD

  1.00 program credit

  • 

    

    Scott T. Tagawa, MD, MS

  • 

    

    Mary-Ellen Taplin, MD

  1.00 program credit

• 

  RestartResume

  Case: Implementing ADT Intensification in mHSPC

  RestartResume

  Case: Implementing ADT Intensification in mHSPC

  MinuteCE®

  Case: Implementing ADT Intensification in mHSPC

  Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD

  1.00 program credit

  • 

    

    Scott T. Tagawa, MD, MS

  • 

    

    Mary-Ellen Taplin, MD

  1.00 program credit

• 

  RestartResume

  Molecular Profiling in mHSPC: Informing Treatment Selection

  RestartResume

  Molecular Profiling in mHSPC: Informing Treatment Selection

  MinuteCE®

  Molecular Profiling in mHSPC: Informing Treatment Selection

  Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD

  1.00 program credit

  • 

    

    Scott T. Tagawa, MD, MS

  • 

    

    Mary-Ellen Taplin, MD

  1.00 program credit

• 

  RestartResume

  ADT Intensification: The Evidence You Can’t Afford to Miss

  RestartResume

  ADT Intensification: The Evidence You Can’t Afford to Miss

  MinuteCE®

  ADT Intensification: The Evidence You Can’t Afford to Miss

  Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD

  1.00 program credit

  • 

    

    Scott T. Tagawa, MD, MS

  • 

    

    Mary-Ellen Taplin, MD

  1.00 program credit

• 

  RestartResume

  Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma

  RestartResume

  Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma

  MinuteCE®

  Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma

  Wenxin Xu, MD; Sandy Srinivas, MD

  1.25 program credits

  • 

    

    Wenxin Xu, MD

  • 

    

    Sandy Srinivas, MD

  1.25 program credits

• 

  RestartResume

  Emerging targeted therapy combination strategies in genitourinary malignancies

  RestartResume

  Emerging targeted therapy combination strategies in genitourinary malignancies

  MinuteCE®

  Emerging targeted therapy combination strategies in genitourinary malignancies

  Ignacio Duran, MD

  1.25 program credits

  • 

    

    Ignacio Duran, MD

  1.25 program credits

• 

  RestartResume

  Emerging immunotherapy combination strategies in genitourinary malignancies

  RestartResume

  Emerging immunotherapy combination strategies in genitourinary malignancies

  MinuteCE®

  Emerging immunotherapy combination strategies in genitourinary malignancies

  Sandy Srinivas, MD

  1.25 program credits

  • 

    

    Sandy Srinivas, MD

  1.25 program credits

• Prev
• 1
• 2
• Next